ACAD — Acadia Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $3.40bn
- $2.44bn
- $1.07bn
Brief: Delaware District Court Rules In Favor Of Acadia In Nuplazid Formulation Patent Litigation
U.S. STOCKS ON THE MOVE-Netflix, Acadia Pharma, CoreWeave
Acadia Pharma soars after favorable court ruling in patent dispute
Brief: Acadia Pharmaceuticals Inc Files For Offering Of Up To 43.6 Million Shares Of Common Stock By The Selling Stockholders - SEC Filing
Acadia Pharmaceuticals Inc Reports Results For The Quarter Ended March 31: Earnings Summary
Brief: Acadia Pharmaceuticals Q1 EPS USD 0.11 Vs. IBES Estimate USD 0.11
Soleno jumps as analysts say US nod for rare disease drug transforms treatment options (updated)
Brief: Saniona, Acadia Announce Initial Positive Results From ACP-711 Phase 1 Study
Acadia Pharmaceuticals Inc Reports Results For The Quarter Ended December 31: Earnings Summary
Brief: Acadia Pharmaceuticals Q4 EPS USD 0.86 Vs. IBES Estimate USD 0.22
Brief: Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
Brief: Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome
Acadia Pharmaceuticals to be part of S&P SmallCap 600, shares rise
Brief: S&P Dow Jones Indices Acadia Pharmaceuticals To Replace Independent Bank Group In S&P Smallcap 600
Brief: Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Acadia Pharmaceuticals Announces Exclusive License Agreement With Saniona For SAN711
Brief: Acadia Pharmaceuticals Inc - On Nov 18, Co Involuntarily Terminates COO Brendan Teehan
Acadia Pharmaceuticals Inc Reports Results For The Quarter Ended In September 30: Earnings Summary
Brief: Acadia Pharmaceuticals Q3 EPS USD 0.2 Vs. IBES Estimate USD 0.14